Lipocine has dosed the first participant in BLOOM, their phase 3 study evaluating LPCN 1154 (oral brexanolone) for postpartum depression.
Advertisement
Advertisement
Trending on Psychiatric Times
1
New National Guidance for Managing Medetomidine Intoxication and Withdrawal
2
Oveporexton Now Available: First and Only Orexin Agonist for Narcolepsy Type 1
3
Closing Diagnostic and Treatment Gaps in Black Children With ADHD
4
Schizo-Obsessed! Untangling the Overlap Between Obsessive Compulsive Disorder and Schizophrenia
5